Bright Minds Biosciences Inc. Common Stock (DRUG) is a publicly traded Healthcare sector company. As of May 21, 2026, DRUG trades at $83.00 with a market cap of $734.04M and a P/E ratio of 0.00. DRUG moved +11.07% today. Year to date, DRUG is +3.46%; over the trailing twelve months it is +155.02%. Its 52-week range spans $0.94 to $123.75. Analyst consensus is strong buy with an average price target of $145.67. Rallies surfaces DRUG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Helus HLP004 Phase 2 Posts 10.4-Point HAM-A Gain; BPL-003 Phase 3 Wins FDA Nod: Helus Pharma’s Phase 2 HLP004 trial in moderate-to-severe GAD showed a 10.4-point mean HAM-A reduction at six weeks, 67% responders and 39% remitters with no serious drug-related adverse events. AtaiBeckley received FDA support for its BPL-003 Phase 3 program, Clearmind’s DSMB endorsed CMND-100 continuation and GH Research reported a $0.79 FY25 loss.
| Metric | Value |
|---|---|
| Price | $83.00 |
| Market Cap | $734.04M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $123.75 |
| 52-Week Low | $0.94 |
| Volume | 41 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover DRUG: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $145.67.